Selatinib ditosilate, an oral, reversible, dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinase receptors, has recently entered clinical development as a potential therapeutic agent for cancer. Here, EGFR is linked to cancer.